

REMARKS

AMENDMENTS TO THE SPECIFICATION

By this amendment, applicants have amended the specification by adding continuing data to the first paragraph. The inserted first paragraph makes reference to the priority applications for the subject application in accordance with 37 C.F.R. §1.78(a)(2)(iii). By the present amendment to the specification, no new matter has been added to the application. Applicants respectively request that this amendment to the specification be entered.

AMENDMENTS TO THE CLAIMS

Claims 1-46 were pending in the subject application. By this Preliminary Amendment, applicants have deleted claims 1-46, without prejudice to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application, and added new claims 47-63.

Support for new claim 47 may be may be found inter alia in the specification, as originally-filed, on page 1, line 13-16, page 7, line 1-3, and line 20-23. Support for new claim 48 may be may be found inter alia in the specification, as originally-filed, on page 4, line 8-9, and page 5, line 6-7. Support for new claim 49 may be may be found inter alia in the specification, as originally-filed, on page 5, line 6-15, and page 6, line 11-15. Support for new claim 50 may be may be found inter alia in the specification, as originally-filed, on page 5, line 9-15, and page 6, line 21-23. Support for new claim 51 may be may be found inter alia in the specification, as originally-filed, on page 3, line 20-22, page 5, line 9-15, and Figure 1. Support for new claim 52 may be may be found inter alia in the specification, as originally-filed, on page 5, line 28 through page 6, line 1, and Table 1. Support for new claim 53 may be may be found inter alia in the specification, as originally-filed, on page 9, line 15. Support for new claim 54 may be may be found inter alia in the specification, as originally-filed, on page 4, line 11-12, and page 5, line 22-26. Support for new claim 55 may be may be found inter alia in the specification, as originally-filed, on page 5,

line 22-26. Support for new claim 56 may be may be found inter alia in the specification, as originally-filed, on page 3, line 25-26, and page 5, line 22-26. Support for new claim 57 may be may be found inter alia in the specification, as originally-filed, on page 5, line 22 through page 6, line 1, and Table 1. Support for new claim 58 may be may be found inter alia in the specification, as originally-filed, on page 19, line 10-15, and page 22, line 24-30. Support for new claim 59 may be may be found inter alia in the specification, as originally-filed, on page 19, line 15-21 and line 26 through page 20, line 5. Support for new claim 60 may be may be found inter alia in the specification, as originally-filed, on page 19, line 26-31. Support for new claim 61 may be may be found inter alia in the specification, as originally-filed, on page 19, line 15-21. Support for new claim 62 may be may be found inter alia in the specification, as originally-filed, on page 21, line 1-27. Support for new claim 63 may be may be found inter alia in the specification, as originally-filed, on page 20, line 26-31.

Applicants maintain that new claims 47-63 raise no issue of new matter and respectfully request that the amendment be entered. Accordingly, upon entry of this Amendment, claims 47-63 will be pending and under examination.

INFORMATION DISCLOSURE STATEMENT

In order to ensure compliance with applicants' duty of disclosure under 37 C.F.R. §1.56 and §1.97(a)-(d), applicants request that the following references be considered and made of record in the above-identified application.

1. Klaus P. Bogeso, et al., "Enhanced D1 Affinity in a Series of Piperazine Ring Substituted 1-Piperazino-3-Arylindanes with Potential Atypical Antipsychotic Activity", Journal of Medicinal Chemistry, vol.38, No.22, 1995, pp. 4380-4392; and
2. EP 0 638 073 B1, published June 21, 2000.


The above-listed references 1 and 2 were cited in the International Search Report issued November 17, 2004 in connection with PCT/DK2004/000545. A copy of the International Search Report is attached hereto.

It is respectfully requested that the Examiner consider the cited references and that the copy of the enclosed Forms PTO/SB/08a and PTO/SB/08b be initialed and returned indicating that such information has been considered. Applicants respectfully request that the Examiner make the cited references of record in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the above-identified application, applicants' undersigned attorney invites the Examiner to telephone the number provided below.

No fee, other than the enclosed \$900.00 filing fee for the subject application, is deemed necessary in connection with filing this Preliminary Amendment. However, if an additional fee is required, authorization is hereby given to charge this fee, and any other fees not covered by the enclosed check to Deposit Account Number 50-3201.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Stephen G. Kalinchak", written over a horizontal line.

Stephen G. Kalinchak
Registration No. 38,747
Lundbeck Research USA, Inc.
215 College Road
Paramus, New Jersey 07652
(201) 350-0781 (phone)
(201) 225-9571 (fax)